VivoSeq
Infectious Disease

Herpes Simplex

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Herpes Simplex is an early-stage landscape with 0 programs across 2 companies. The most active players are GSK, Gilead.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalGilead logo

Gilead

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed12 · 92%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

13 trials

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant
Completed·GSK logoGSK·Phase 2·NCT00697567·80 enrolled
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000635·25 enrolled
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
Completed·GSK logoGSK·Phase 3·NCT00224484·5,960 enrolled
A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis
Completed·YYung Shin Pharm. Ind. Co., Ltd.·Phase 2·NCT02207881·40 enrolled
Zinc for the Treatment of Herpes Simplex Labialis (HSL)
Completed·IIntegrative Medicine Institute·Phase 3·NCT00809809·157 enrolled
Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS
Completed·Gilead logoGilead·N/A·NCT00002181
Phase III Study of ASP2151 in Herpes Simplex Patients
Completed·MMaruho Co., Ltd.·Phase 3·NCT01959295·468 enrolled
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine
Completed·GSK logoGSK·Phase 3·NCT00224471·671 enrolled
Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
Completed·MMedivir·Phase 3·NCT00375570·254 enrolled
Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects
Completed·GSK logoGSK·Phase 3·NCT00698568·7,460 enrolled
Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex
Completed·IIveriapharma LLC·Phase 2·NCT06089252·30 enrolled
Open-label Study of ASP2151 in Herpes Simplex Patients
Completed·MMaruho Co., Ltd.·Phase 3·NCT02209324·275 enrolled
The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children
Withdrawn·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001054

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)